DTI 015
Alternative Names: BCNU - Direct Therapeutics; Carmustine - Direct Therapeutics; Injectable carmustine - Direct TherapeuticsLatest Information Update: 21 Oct 2021
At a glance
- Originator Direct Therapeutics
- Class Antineoplastics; Nitrosourea compounds
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma; Liver cancer
Most Recent Events
- 26 Apr 2007 Discontinued - Phase-I for Liver cancer in USA (Intratumoural)
- 26 Apr 2007 Discontinued - Phase-II for Glioblastoma in USA (Intratumoural)
- 24 Oct 2002 Approval to begin a new European study of DTI 015 in patients with newly diagnosed high-grade glioma has been granted by the United Kingdom's Medicines Control Agency